Trigger Finger Corticosteroid Injection With and Without Local Anesthetic

Trigger Finger Clinical Trial

Official title:

Trigger Finger Corticosteroid Injection With and Without Local Anesthetic; a Randomized, Double Blind Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04023695
• Other study ID #: 1064521-12
• Status: Completed
• Phase: Phase 4
• Start date: October 1, 2017
• Est. completion date: August 30, 2018

Study information

• Verified date: December 2019
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Steroid injection is the first line treatment for trigger finger. Steroid injection is sometimes mixed with a local anesthetic.

Description:

The treatment of trigger finger involves an injection of corticosteroid. Corticosteroid treats the underlying inflammatory pathology. Some surgeons add lidocaine with epinephrine as a local anesthetic with the injection. Lidocaine with epinephrine is associated with a burning sensation and may be the primary pain associated with the injection. We hypothesize that a corticosteroid injection without lidocaine with epinephrine will be less painful, and equally effective in treating trigger finger

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: August 30, 2018
• Est. primary completion date: August 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years old with trigger finger

Exclusion Criteria:

• Preference for open trigger finger release

• Not a candidate for corticosteroid injection

• Contraindication to lidocaine with epinephrine

Related Conditions & MeSH terms

• Trigger Finger
• Trigger Finger Disorder

Intervention

Drug:
• Corticosteroid with lidocaine with epinephrine
Trigger finger injection
• Corticosteroid with normal saline
Trigger finger injection

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain Outcome: Visual Analog Scale	Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever	Assessed 1 minute after injection (in clinic)
Primary	Pain Outcome: Visual Analog Scale	Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever	Assessed after 24 hours after injection (by phone)